Modelling population-level impact to inform target product profiles for childhood malaria vaccines

@inproceedings{Hogan2018ModellingPI,
  title={Modelling population-level impact to inform target product profiles for childhood malaria vaccines},
  author={Alexandra B Hogan and Peter Winskill and Robert Verity and Jamie T. Griffin and Azra C. Ghani},
  booktitle={BMC medicine},
  year={2018}
}
BackgroundThe RTS,S/AS01 vaccine for Plasmodium falciparum malaria demonstrated moderate efficacy in 5–17-month-old children in phase 3 trials, and from 2018, the vaccine will be evaluated through a large-scale pilot implementation program. Work is ongoing to optimise this vaccine, with higher efficacy for a different schedule demonstrated in a phase 2a challenge study. The objective of our study was to investigate the population-level impact of a modified RTS,S/AS01 schedule and dose amount in… CONTINUE READING
BETA
35
Twitter Mentions

Similar Papers

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

a language and environment for statistical computing

R R Core Team.
  • Vienna: R Foundation for Statistical Computing; 2017. https://www.r-project.org/ Hogan et al. BMC Medicine
  • 2018
VIEW 1 EXCERPT

a modelling study

PGT Walker, JT Griffin, NM Ferguson, burden Ghani AC. Estimating the most efficient allocation malaria, Africa transmission in
  • Lancet Glob Health. 2016;4:e474–84. https://doi.org/10.1016/S2214-109X(16)30073-0. Hogan et al. BMC Medicine
  • 2018

Efficacy and safety of RTS , S / AS 01 malaria vaccine with or without a booster dose in infants and children in Africa : final results of a phase 3 , individually randomised , controlled trial

JA Regules, SB Cicatelli, +3 authors JE Moon
  • Lancet
  • 2015